The use of 68Ga-DOTATATE PET/CT, which is already approved for NETs [50], could be explored in selected SSTR2-positive HCC, with prospective evaluation of diagnostic performance and clinical utility. This evidence concerns the gene SSTR2 and hepatocellular carcinoma.